Targeting Slc16a/Mct Lactate Transporters in Cancer Therapeutics

癌症治疗中的靶向 Slc16a/Mct 乳酸转运蛋白

• 批准号: 8435368
• 负责人: John L. Cleveland
• 金额: $ 74.48万
• 依托单位: SCRIPPS FLORIDA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-02-29 至 2016-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8435368
• 关键词: Acids; Adverse effects; Amino Acid Transport System L; Amino Acid Transporter; Antineoplastic Agents; B-Cell Lymphomas; B-Cell Neoplasm; B-Lymphocytes; Binding; Breast Adenocarcinoma; Breast Cancer Cell; Breast Cancer Model; Catabolism; Cells; Chemicals; Chemoprevention; Coin; Data; Derivation procedure; Development; Doxycycline; Drug Kinetics; Enzymes; Essential Amino Acids; Genetic; Genetic Transcription; Glucose; Glutamine; Growth; Homeostasis; Homology Modeling; Housing; Human; Inhibitory Concentration 50; Knockout Mice; Lactate Transporter; Lactic acid; Lead; Ligands; Lymphoma; Maintenance; Malignant Neoplasms; Mammary Neoplasms; Metabolic; Metabolism; Metformin; Mitochondria; Modeling; Monocarboxylic Acid Transporters; Mouse Mammary Tumor Virus; Mus; Mutagenesis; Mutation; New Agents; Oncogene Proteins; Organelles; Organic Chemistry; Oxidative Phosphorylation; Pathway interactions; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phenotype; Phenylalanine; Premalignant; Production; Property; Pyruvate; Pyruvate Metabolism Pathway; Research; Role; Route; Safety; Structure; System; Testing; Therapeutic; Therapeutic Studies; Transgenic Mice; Transgenic Model; Ursidae Family; Warburg Effect; Woman; aerobic glycolysis; cancer cell; cancer genetics; cancer therapy; cell growth; design; efficacy testing; glutamine analog; improved; in vivo; inhibitor/antagonist; innovation; malignant breast neoplasm; malignant state; mutant; neoplastic; neoplastic cell; novel; novel therapeutics; overexpression; prevent; resistance mechanism; response; tumor; tumor metabolism; tumorigenesis; uptake

DESCRIPTION (provided by applicant): A hallmark of cancer is glucose catabolism via aerobic glycolysis (the Warburg effect). This phenotype includes marked increases in the expression of glucose and amino acid transporters and a switch in the functions of mitochondria to an anabolic organelle. The combined effect is a marked diversion (~95%) of pyruvate towards lactate, which is exported out of the cancer cell via dedicated 12-transmembrane-pass monocarboxylic acid transporters coined Mct1 and Mct4, which we have shown are overexpressed and inversely regulated in several tumor types. Myc oncoproteins are activated in nearly 70% of human cancers, where they orchestrate wholesale changes in gene transcription that drive tumorigenesis, including a cast of metabolic enzymes. We have shown that most glycolytic enzymes and amino acid transporters are elevated in premalignant Myc-expressing B cells, and that this response is amplified in Myc-driven lymphoma. Accordingly, premalignant and neoplastic Myc-expressing B cells produce excess levels of lactate. Notably, we have shown that Myc coordinates lactate homeostasis in the cell by directly inducing the transcription of Mct1, and that elevated MCT1 is a hallmark of human malignancies with MYC involvement. Importantly, our Multi-PI research team, which combines expertise in cancer genetics and therapeutics (PI Dr. John Cleveland) with a world leader in synthetic organic chemistry and the derivation of novel therapeutics (PI Dr. William Roush), has demonstrated that established and new in-house agents that inhibit Mct1 disable human lymphoma and breast cancer cell metabolism and proliferation, and impair tumorigenesis without side effects. Thus, we hypothesize that blocking Mct1- and/or Mct4-directed lactate transport is an innovative, widely applicable strategy for anti-cancer therapy. Using both mouse and human tumor models, in Aim 1 we test the hypothesis that Mct1 is necessary for both the development and maintenance of Myc-driven lymphoma, and in Aim 2 we test the contribution of both Mct1 and Mct4 to the development and maintenance of breast cancer. In Aim 3 the drug-likeness of our lead Mct1 inhibitors will be optimized using reiterative efficacy, medicinal chemistry and DMPK screens. We will also develop, validate and refine Mct4 inhibitors and develop pan-Mct1/Mct4 inhibitors. These new agents will be tested for efficacy, safety, and selectivity using our mouse and human lymphoma and breast cancer models. In Aim 4 we will exploit the increased expression of the glutamine (e.g., Asct2) and large neutral amino acid transporters (e.g., LAT1) manifest in human malignancies. Specifically, we will chemically tether our anti-Mct inhibitors to ligands for these transporters, which we have shown augments their tumor cell delivery and potency. The efficacy, potency, selectivity and safety of these novel conjugates will be tested using lymphoma and breast cancer models. We submit that the assembled research team will generate a cast of new, efficacious and safe anti-cancer agents that will have applications in chemoprevention and as broad-spectrum therapeutics.

描述（由申请人提供）：癌症的一个标志是通过有氧糖酵解（瓦尔堡效应）的葡萄糖代谢。这种表型包括葡萄糖和氨基酸转运蛋白表达的显著增加以及线粒体功能向合成代谢细胞器的转换。综合效应是丙酮酸显著转向（~95%）乳酸，乳酸通过专门的12跨膜单羧酸转运蛋白Mct 1和Mct 4从癌细胞中输出，我们已经证明Mct 1和Mct 4在几种肿瘤类型中过表达和反向调节。Myc癌蛋白在近70%的人类癌症中被激活，它们协调基因转录的大规模变化，这些变化驱动肿瘤发生，包括一系列代谢酶。我们已经证明，大多数糖酵解酶和氨基酸转运蛋白在癌前表达Myc的B细胞中升高，并且这种反应在Myc驱动的淋巴瘤中被放大。 因此，癌前和肿瘤性Myc表达B细胞产生过量的乳酸。值得注意的是，我们已经表明，Myc协调乳酸稳态在细胞中直接诱导转录的Mct 1，和升高的MCT 1是人类恶性肿瘤与MYC参与的标志。重要的是，我们的Multi-PI研究团队将癌症遗传学和治疗学方面的专业知识（PI John Cleveland博士）与合成有机化学和新型治疗剂衍生方面的世界领先者（PI William Bennh博士）相结合，已经证明了抑制Mct 1的现有和新的内部药物可以使人类淋巴瘤和乳腺癌细胞代谢和增殖丧失能力，并在没有副作用的情况下损害肿瘤发生。因此，我们假设阻断Mct 1和/或Mct 4介导的乳酸转运是一种创新的、广泛适用的抗癌治疗策略。使用小鼠和人肿瘤模型，在目标1中，我们测试了Mct 1对于Myc驱动的淋巴瘤的发展和维持都是必要的假设，在目标2中，我们测试了Mct 1和Mct 4对乳腺癌的发展和维持的贡献。在目标3中，我们的主要Mct 1抑制剂的药物相似性将使用药效、药物化学和DMPK筛选进行优化。我们还将开发，验证和完善Mct 4抑制剂，并开发泛Mct 1/Mct 4抑制剂。这些新药物将使用我们的小鼠和人类淋巴瘤和乳腺癌模型进行疗效，安全性和选择性测试。在目标4中，我们将利用谷氨酰胺的表达增加（例如，Asct 2）和大的中性氨基酸转运蛋白（例如，LAT 1）在人类恶性肿瘤中表现。具体来说，我们将用化学方法将我们的抗Mct抑制剂与这些转运蛋白的配体结合，我们已经证明这会增强它们的肿瘤细胞递送和效力。这些新型缀合物的功效、效力、选择性和安全性将使用淋巴瘤和乳腺癌模型进行测试。我们认为，组装的研究小组将产生一系列新的，有效的和安全的抗癌剂，将在化学预防和广谱治疗应用。